Kevin Patrick Moran Net Worth

The estimated Net Worth of Kevin Patrick Moran is at least $2.54 Milión dollars as of 29 July 2024. Mr Moran owns over 2,251 units of Vanda Pharmaceuticals Inc stock worth over $1,125,514 and over the last 4 years he sold VNDA stock worth over $654,680. In addition, he makes $755,635 as Sr. VP a CFO & Treasurer at Vanda Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Moran VNDA stock SEC Form 4 insiders trading

Mr has made over 10 trades of the Vanda Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,251 units of VNDA stock worth $13,326 on 29 July 2024.

The largest trade he's ever made was selling 16,000 units of Vanda Pharmaceuticals Inc stock on 15 June 2023 worth over $100,640. On average, Mr trades about 5,903 units every 89 days since 2020. As of 29 July 2024 he still owns at least 228,763 units of Vanda Pharmaceuticals Inc stock.

You can see the complete history of Mr Moran stock trades at the bottom of the page.

Mr. Kevin Patrick Moran biography

Kevin Patrick Moran is the Sr. VP, CFO & Treasurer at Vanda Pharmaceuticals Inc.

What is the salary of Mr Moran?

As the Sr. VP a CFO & Treasurer of Vanda Pharmaceuticals Inc, the total compensation of Mr Moran at Vanda Pharmaceuticals Inc is $755,635. There are 6 executives at Vanda Pharmaceuticals Inc getting paid more, with Mihael Polymeropoulos having the highest compensation of $4,278,140.

How old is Mr Moran?

Mr Moran is 37, he's been the Sr. VP a CFO & Treasurer of Vanda Pharmaceuticals Inc since . There are 14 older and 1 younger executives at Vanda Pharmaceuticals Inc. The oldest executive at Vanda Pharmaceuticals Inc is Richard Dugan, 78, who is the Independent Director.

What's Mr Moran's mailing address?

Kevin's mailing address filed with the SEC is 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON, DC, 20037.

Insiders trading at Vanda Pharmaceuticals Inc

Over the last 18 years, insiders at Vanda Pharmaceuticals Inc have traded over $267,060,716 worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth $25,606,507 . The most active insiders traders include Kevin Ctang Capital Managem..., Nicole Vitullo a Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $546,607. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth $13,326.

What does Vanda Pharmaceuticals Inc do?

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Complete history of Mr Moran stock trades at Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc executives and stock owners

Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mihael Polymeropoulos,
  President, Chief Executive Officer, Director
• Timothy Williams,
  Senior Vice President, General Counsel, Secretary
• Gunther Birznieks,
  Senior Vice President - Business Development
• Dr. Mihael H. Polymeropoulos M.D.,
  Founder, Pres, CEO & Chairman of The Board
• Dr. Mihael H. Polymeropoulos,
  Founder, Pres, CEO & Director
• Joakim Wijkstrom,
  Sr. VP & Chief Marketing Officer
• Kevin Patrick Moran,
  Sr. VP, CFO & Treasurer
• Timothy Williams,
  Sr. VP, Gen. Counsel & Sec.
• Phaedra Chrousos,
  Independent Director
• Anne Ward,
  Independent Director
• H. Thomas Watkins,
  Independent Chairman of the Board
• Richard Dugan,
  Independent Director
• Stephen Mitchell,
  Independent Director
• Aranthan Jones,
  Chief Corporate Affairs and Communications Officer
• Joakim Wijkstrom,
  Senior Vice President, Chief Marketing Officer
• Kevin Moran,
  Acting Chief Financial Officer, Vice President, Treasurer
• Elizabeth Van Every,
  Head of Corp. Affairs
• Scott L. Howell,
  Chief People Officer
• Kenneth Bate,
  Director
• Michael F Cola,
  Director
• James E Deerfield Mgmt L.P....,
  
• Paolo Baroldi,
  Chief Medical Officer
• Vincent Milano,
  Director
• Steven A Shallcross,
  Sr. VP, CFO, Treasurer
• Albert W. Gianchetti,
  Sr.VP,Chief Commercial Officer
• Tage Honore,
  
• Richard L. Gulino,
  SVP & General Counsel
• James Patrick Kelly,
  EVP & Chief Financial Officer
• Gian Piero Reverberi,
  SVP & Chief Commercial Officer
• James B Tananbaum,
  Director
• Capital Ii Llccare Capital ...,
  
• Robert J More,
  10% owner
• Nicole Vitullo,
  10% owner
• Management Co Ii Llcprospec...,
  
• Brian H Dovey,
  10% owner
• Deepak Shripad Phadke,
  Vice President Manufacturing
• Ventures Iv Lprho Ventures ...,
  
• James C Blair,
  10% owner
• Inc /De Medimmune,
  10% owner
• Wayne T Hockmeyer,
  Director
• Ventures Iv Lprho Managemen...,
  
• Vi Associates, L.P. Dp,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Venture Partners Ii Lpprosp...,
  
• Jesse I Treu,
  10% owner
• Sciences Investment Fund Pt...,
  
• Kathleen K Schoemaker,
  10% owner
• Thomas Edward Gibbs,
  SVP, Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Howard H Pien,
  Director
• Steven K Galson,
  Director
• Robert Repella,
  SVP & Chief Commercial Officer
• Stephanie Rast Irish,
  Sr. VP, Acting CFO/Treasurer
• John Joseph Feeney,
  Acting Chief Medical Officer
• Argeris N Karabelas,
  Chairman of the Board
• Brian K Halak,
  Director
• William D Clark,
  Sr VP, Chief Business Officer
• David Russ Ramsay,
  Director
• Kevin Ctang Capital Managem...,